Specialist Cardiac Safety Screening

High-quality cardiac safety screening services, including GLP hERG and CiPA assays

CONTACT US

Reliably evaluate the proarrhythmic and cardiotoxic liabilities of your compounds

The cardiac safety screening assays we offer include:

Cardiac ion channel profiling

Assessment of core cardiac ion channels: hERG, NaV1.5 and CaV1.2

Expanded CiPA cardiac panel: hERG, NaV1.5 (late current), CaV1.2, Kir2.1, KV4.3_KChIP and KV7.1_MinK

Additional cardiac channels: HCN4 and KV1.5

GLP hERG testing

GLP hERG profiling to support Investigational New Drug (IND) applications

Performed in accordance with current ICH S7B guidelines

Read about GLP hERG testing

hiPSC cardiomyocyte assay for early cardiac de-risking

High throughput/high resolution assessment of compound effects on action potential morphology using voltage dye

Predicts free compound exposure associated with 10ms change in clinical QTc following both acute (30 min)and chronic (24 h) treatment

Defines probability of clinical QRS liability

Aligns with current ICH S7B guidelines

hiPSC cardiomyocyte current clamp profiling

Assess proarrhythmic potential of compounds via manual current clamp

hiPSC cardiomyocyte toxicity testing

Functionally assess the viability following chronic compound treatment (up to 72 h) using high-throughput impedance platform

Cardiac safety ion channel experts

By working with us you benefit from:

Exceptional ion channel electrophysiology and drug discovery expertise.

A team of experienced cell biologists to create novel cell lines.

High quality, cost-effective compound screening.

Detailed characterisation of lead compounds in a range of high quality assays.

Translational services including confirmation of efficacy in stem cell and other phenotypic models.

Flexible approach that best suits your project and budget.

Rapid turn-around times, reporting and data interpretation by highly experienced ion channel scientists.

Request More Information

Our expertise in GLP hERG screening is demonstrated in the case study GLP hERG Assay Validation Following ICH E14/S7B 2022 Q&A Best Practice Guidelines.

Top: Example traces in vehicle, dofetilide and E-4031. Bottom: Corresponding IT plot. IC50 values generated were within 2-fold of the values reported in the ICH E14/S7B training material. Read more about GLP hERG assay validation.

Webinar recording: In Vitro Assessment of Cardiac Risk in Drug Discovery

Download the recording of this webinar to learn how an hiPSC-CM model can help provide clear decision-making data for your project team that can avoid costly issues related to QTc and QRS cardiac liabilities in the clinic.

Recording includes presentations and Q&A:

Derek Leishman (VP Translational and Quantitative Toxicology, Eli Lilly and Company).

Steve Jenkinson (VP Drug Discovery and Safety, Metrion).

Cardiac Safety Screening Resource Library
A clinically translatable hiPSC cardiomyocyte model to predict QTc and QRS cardiac risk

Presented at the SPS meeting in September 2024, Dr Steve Jenkinson presents Metrion’s human induced pluripotent stem cell (hiPSC)-derived cardiomyocyte assay, an advanced tool, providing key advantages, for early cardiac derisking in drug discovery.

The state of the art in secondary pharmacology and its impact on the safety of new medicines

Jenkinson, Steve Advanced In Vitro Screening of New Drugs for Proarrhythmic Activity, Genetic Engineering News. 2024 44:5, 48-50

VIEW ALL RESOURCES
Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram